Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition

View through CrossRef
<div>Abstract<p>The molecular basis of therapy resistance in multiple myeloma remains poorly understood. In this study, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary multiple myeloma cells from patient bone marrow. This approach uncovered cellular heterogeneity and phenotypic plasticity of multiple myeloma cells across a spectrum of CD138 expression, accompanied by drastic epigenetic alterations. Notably, therapy-resistant subpopulations were identified within a minor fraction of CD138<sup>–</sup> multiple myeloma cells, which were shown via CRISPR/Cas9 screening to be vulnerable to splicing pathway inhibition. Consistently, this fraction of CD138<sup>–</sup> multiple myeloma cells showed increased differential splicing associated with overexpression of SR protein family splicing factors. Among these splicing factors, RBM39 was overexpressed in therapy-resistant cells and involved in aberrant splicing. Both genetic and pharmacologic RBM39 inhibition exhibited a significant lethal effect on multiple myeloma cells. Collectively, our findings identify distinct therapy-resistant multiple myeloma subpopulations and highlight targeting the splicing pathway as a promising therapeutic strategy.</p>Significance:<p>Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138<sup>–</sup> fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138<sup>−</sup> cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39.</p><p><a href="https://aacrjournals.org/bloodcancerdiscov/article-abstract/doi/10.1158/2643-3230.BCD-25-0308" target="_blank"><i>See related commentary by Maron and Abdel-Wahab, p. 535</i></a></p></div>
Title: Data from Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition
Description:
<div>Abstract<p>The molecular basis of therapy resistance in multiple myeloma remains poorly understood.
In this study, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary multiple myeloma cells from patient bone marrow.
This approach uncovered cellular heterogeneity and phenotypic plasticity of multiple myeloma cells across a spectrum of CD138 expression, accompanied by drastic epigenetic alterations.
Notably, therapy-resistant subpopulations were identified within a minor fraction of CD138<sup>–</sup> multiple myeloma cells, which were shown via CRISPR/Cas9 screening to be vulnerable to splicing pathway inhibition.
Consistently, this fraction of CD138<sup>–</sup> multiple myeloma cells showed increased differential splicing associated with overexpression of SR protein family splicing factors.
Among these splicing factors, RBM39 was overexpressed in therapy-resistant cells and involved in aberrant splicing.
Both genetic and pharmacologic RBM39 inhibition exhibited a significant lethal effect on multiple myeloma cells.
Collectively, our findings identify distinct therapy-resistant multiple myeloma subpopulations and highlight targeting the splicing pathway as a promising therapeutic strategy.
</p>Significance:<p>Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138<sup>–</sup> fraction of multiple myeloma cells.
These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138<sup>−</sup> cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39.
</p><p><a href="https://aacrjournals.
org/bloodcancerdiscov/article-abstract/doi/10.
1158/2643-3230.
BCD-25-0308" target="_blank"><i>See related commentary by Maron and Abdel-Wahab, p.
535</i></a></p></div>.

Related Results

Characterisation and relevance of CD138‐negative plasma cells in plasma cell myeloma
Characterisation and relevance of CD138‐negative plasma cells in plasma cell myeloma
SummaryIntroduction:  The use of CD138 to isolate CD138 + plasma cells (PCs) from plasma cell myeloma (PCM) patients’ bone marrow samples has been used extensively in myeloma resea...
Abstract 778: Dysregulation of alternative mRNA splicing by oncogenic KRAS in lung adenocarcinoma
Abstract 778: Dysregulation of alternative mRNA splicing by oncogenic KRAS in lung adenocarcinoma
Abstract Alternative mRNA splicing is dysregulated in many cancers including lung adenocarcinoma. These aberrant splicing events can sometimes be explained by mutati...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract Introduction Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Regulation of Alternative Splicing in B-Cell ALL By DYRK1A
Regulation of Alternative Splicing in B-Cell ALL By DYRK1A
DYRK1A, located in the Down syndrome critical region of chromosome 21, is a serine and threonine kinase that controls multiple cellular processes including apoptosis, cell cycle, t...
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Challenging Management of Postoperative Empyema: A Case Report with Literature Review
Abstract Introduction: Pleural empyema is the collection of pus within the pleural cavity, typically arising as a complication of pneumonia, chest trauma, thoracic surgery, or bact...
Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines
Abstract Bortezomib is the first proteasome inhibitor in clinical use. It is particularly effective in myeloma compared with other cancers; as a single agent, its re...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...

Back to Top